Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France
Study Overview
Primary Objective:
To describe the lung, spleen and liver outcomes of olipudase alfa
Secondary Objectives:
- To describe the patient's characteristics
- To describe conditions of olipudase alfa use
- To describe safety data related to the use of olipudase alfa
- To describe complementary effectiveness outcomes parameters
Study details
Approximate duration of enrollment: 18 months
Total study duration: approximately 3 years
This is a national, multicenter observational retrospective and prospective cohort data
collection study. Retrospective is defined as collection of data from all patients, including
deceased patients, who were already on early access olipudase alfa in France before the start
of this study.
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acid Sphingomyelinase Deficiency (ASMD)
-
Gender: All
Inclusion Criteria:
- The patient, or the patient's parent(s)/guardian(s), has signed written informed consent.
- Patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France (ie, nominative compassionate use, pre marketing authorization early access, post marketing authorization early access).
- The patient has documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes, or cultured fibroblasts.
- Male and female patients of all ages.
Exclusion Criteria:
- The patient or legal guardian(s) who has not received information notice or who opposes to data collection.
- Patient who died before study initiation and who was opposed to data collection for research purpose when he/she was alive.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Updated on
27 Mar 2024.
Study ID: NCT05359276
Find a Study Location to Connect
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact